DCTH Delcath Systems, Inc.

NASDAQ
$20.55

Delcath Systems, Inc. (DCTH) is expected to report earnings on February 8, 2027, before the market open. The consensus earnings estimate is a loss of $0.10 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +10.6% since its last earnings release on November 9, 2026.

Delcath Systems Beat Consensus Estimates, Raises Guidance
Monday, November 9, 2026 · 8:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 8
Monday · 8:00 AM ET
Earnings Whisper
-
vs ($0.10)
Rev est $26.25M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $20.71

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Sector

Healthcare

Industry

Medical Instruments/Supply

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.